New Technology– category –
-
Zentek Secures US Patent for ZenGUARD™ Graphene-Based Technology, Bolstering IP Protection and Paving Way for US Market Entry
Newsfile Corp. Canada Overview Zentek Ltd. announced the issuance of U.S. Patent No. 12,616,206 covering its foundational ZenGUARD™ graphene-based technology. This new patent complements existing Canadian patents for personal protective ... -
Nanoscale Gold Metamaterials Supercharge Heat Transfer Across Tiny Gaps by up to 4x, Revolutionizing Thermal Management in Miniature Electronics
ScienceDaily USA Overview Scientists have achieved a breakthrough by using nanoscale gold metamaterials to significantly enhance heat transfer across tiny gaps, delivering up to four times the energy flux compared to conventional equival... -
Transfer Learning Accelerates Search for New Physics in the Universe by Up to 10x, Reducing Costly Simulations and Revolutionizing Materials and Quantum Physics Research
ScienceDaily USA Overview Scientists discovered that an AI transfer learning approach can significantly accelerate the search for new physics in the universe, potentially reducing the need for costly and time-consuming simulations by up ... -
Park Systems Invests in Advanced Nanoscale Metrology Portfolio to Drive Next-Gen 3D Packaging and Logic Research
PR Newswire USA Overview Park Systems, a global leader in AFM and nanoscale metrology, announced a strategic investment in its advanced metrology portfolio for 3D packaging and logic research. This initiative aims to accelerate the evolu... -
FAPI-46 Theranostic Agent Shows Promising Survival Benefits in Glioblastoma Peripheral Models, But Brain-Blood Barrier Permeation Remains a Challenge
Journal of Nuclear Medicine USA Overview A study on glioblastoma evaluated FAP inhibitor (FAPI)-46 as a theranostic agent targeting fibroblast activation protein (FAP). In vivo, diagnostic [68Ga]Ga-FAPI-46 demonstrated high tumor uptake,... -
Non-Viral CRISPR/Cas9 HDR Platform Enables Stable Genetic Engineering of Solid Tumor Models, Overcoming Viral Vector Challenges
bioRxiv (Preprint) USA Overview This preprint reports research on a non-viral CRISPR/Cas9 Homology-Directed Repair (HDR) platform for stable genetic engineering of solid tumor models. This approach enables precise genome modification and... -
FDA Expedited Pathway Guide: Strategic Selection of Fast Track, Breakthrough Therapy, and RMAT
Boyd Consultants USA Overview The FDA offers several expedited programs to accelerate innovative drug development, including Fast Track, Breakthrough Therapy, and Regenerative Medicine Advanced Therapy (RMAT). This article outlines the d... -
Allogeneic BCMA CAR T Therapy CB-011 Achieves Deep Responses and Confirms Immune Cloaking in Multiple Myeloma Phase 1 Trial
The ASCO Post USA Overview CB-011, the first allogeneic anti-BCMA CAR T-cell therapy incorporating immune cloaking technology, achieved a high overall response rate (ORR) in its Phase 1 CaMMouflage trial for relapsed/refractory heavily p... -
Caribou Biosciences’ Off-the-Shelf Allogeneic CAR T Vispa-cel Shows Superior PFS to Approved Autologous CAR T Therapies in Lymphoma Phase 1
Fierce Biotech USA Overview Caribou Biosciences announced promising median progression-free survival (PFS) data from its Phase 1 clinical trial of vispacabtagene regedleucel (vispa-cel), an off-the-shelf allogeneic CAR T-cell therapy for... -
Cellectis’ Lasme-cel Receives FDA RMAT Designation as First Allogeneic CAR T in Pivotal Trial for R/R B-ALL, EHA Data Confirms Efficacy
Stock Titan (Cellectis SEC Filing) USA Overview Cellectis announced that its CD22-targeting allogeneic CAR T-cell therapy candidate, lasme-cel (UCART22), has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA...
